NCT Number: NCT01686711
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Hirosaki-shi, Aomori, Japan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
- Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.
Exclusion criteria
- Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.
- Others who are assessed to be ineligible for the study by the investigator or subinvestigator.
Treatment and study plan
AD-4833 30 mg
DrugPlacebo
DrugPrimary outcomes
-
Glycosylated Hemoglobin (HbA1c)
Time frame: 16 weeks
Measurement of change in HbA1c (ratio of hemoglobin bound to glucose)
Sponsors and collaborators
Lead sponsor
Takeda
Industry
Registry information
Official study title
A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy
Important dates
- Study start
- 2012
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Sep 18, 2012
- Registry last updated
- Aug 31, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dysvascular Amputation Self-Management of Health
NCT04083456
Amputation, Arterial Occlusive Diseases
Aurora, Colorado, United States
View Trial DetailsResidual Gastric Volume Measured by Ultrasound in Diabetic Surgical Population Versus Non-diabetic Surgical Population.
NCT05435157
Diabetes Mellitus, Endocrine System Diseases
Salamanca, Spain
View Trial DetailsLinks Between Inflammation and Cardiometabolic Diseases
NCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsOptimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)
NCT04040634
Cardiovascular Diseases, Cognition Disorders
Maceió, Alagoas, Brazil
View Trial Details